Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased ... office in Charlottetown , PEI.  Bioenterprise ... Edward Island ADAPT Council for the commercialization of agricultural ... to working with PEI ADAPT.  They have been at ... than a decade," explains Dave Smardon , President ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 ... company dedicated to improving cancer surgeries, announced today that ... lead fluorescent cancer illuminator, AVB-620, in women with primary, ... trial, the company also welcomed the addition of ... affairs. The open label, dose escalation study ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... Technologies, Inc.,(OTC Bulletin Board: AVXT) (the "Company") today ... bridge loan financing pursuant to a Convertible Note,and ... to Convertible,Note and Warrant Purchase Agreement (collectively the ... promissory notes,(the "Notes") in the aggregate principal amount ...
... SAN DIEGO, Oct. 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... ANA773 in,patients chronically infected with hepatitis C virus (HCV) ... ANA773 in both healthy volunteers and,HCV patients. ANA773 is ... of the study, patients in the first cohort will ...
... (Nasdaq:,CEPH) today announced that its Analyst Day in New ... be webcast live on the investor relations section of,its ... will review the company,s business,strategy, marketing plan and research ... November 5, 2008 beginning at,approximately 12:30 p.m. EST and ...
Cached Biology Technology:AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing 2Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 2Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 3Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 4Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 5Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... simulations, researchers at the University of Illinois have demonstrated a ... forth through a nanopore capacitor in a semiconductor chip. The ... genomes quickly and affordably., Being able to sequence a human ... insurance companies are willing to pay) could open a new ...
... BOWLING GREEN, O.Bowling Green State University biology undergraduates will ... genomics while they learn. The University has been selected ... new Microbial Genome Annotation research program through the U.S. ... Analysis of the genomes of microorganisms is an important ...
... Investigators at the University of Rochester Medical Center have ... of hope for children with Batten disease a ... robs them of their abilities to see, reason and ... The study, highlighted in the January edition of ...
Cached Biology News:New technique could dramatically lower costs of DNA sequencing 2BGSU undergraduates to pilot groundbreaking genome project 2BGSU undergraduates to pilot groundbreaking genome project 3Research unveils new hope for deadly childhood disease 2
IHC Detection Kit (Broad Spectrum AEC)....
...
...
... to L1 Cell Adhesion Molecule ... in Xq28, is involved in three distinct ... of Sylvius); 2) MASA (mental retardation, aphasia, ... (spastic paraplegia). Immunogen: ...
Biology Products: